According to the International Myeloma Working Group, diagnostic criteria include a serum M-protein < 3 g/dL, <10% clonal plasma cells in the bone marrow, and the absence of clinical features attributable to plasma-cell proliferative disease such as hypercalcemia, renal impairment, anemia, or bone lesions. Here, MYOM2 is linked to Hypercalcemia.